GoodRx (NASDAQ:GDRX) Given New $5.00 Price Target at JPMorgan Chase & Co.

GoodRx (NASDAQ:GDRX) had its target price lowered by JPMorgan Chase & Co. from $6.00 to $5.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other research analysts have also recently issued reports about the company. UBS Group lowered their target price on GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. TD Cowen lowered their price objective on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday. Raymond James Financial cut GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Finally, Mizuho dropped their price objective on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GoodRx presently has a consensus rating of “Hold” and an average target price of $5.52.

GoodRx Trading Down 1.0%

Shares of GDRX opened at $3.03 on Tuesday. GoodRx has a 52-week low of $2.95 and a 52-week high of $5.81. The stock has a market cap of $1.05 billion, a PE ratio of 33.67, a price-to-earnings-growth ratio of 1.57 and a beta of 1.19. The firm’s fifty day moving average is $3.97 and its two-hundred day moving average is $4.25. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $196.03 million during the quarter, compared to analysts’ expectations of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.08 earnings per share. GoodRx has set its FY 2025 guidance at EPS. Research analysts forecast that GoodRx will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total transaction of $95,084.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.17% of the company’s stock.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently made changes to their positions in GDRX. Citizens Financial Group Inc. RI acquired a new position in shares of GoodRx in the 1st quarter worth approximately $44,000. Jump Financial LLC acquired a new position in GoodRx during the first quarter worth $49,000. Cetera Investment Advisers purchased a new position in shares of GoodRx during the second quarter worth $50,000. Walled Lake Planning & Wealth Management LLC acquired a new stake in shares of GoodRx in the second quarter valued at $55,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of GoodRx by 202.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after buying an additional 7,580 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.